Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Status: Enrolling
Updated:  12/31/1969
University of Chicago
845
mi
from 02139
Chicago, IL
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184
Status: Enrolling
Updated: 12/31/1969
University of Chicago
845
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1047
mi
from 02139
Iowa City, IA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1047
mi
from 02139
Iowa City, IA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2275
mi
from 02139
Tucson, AZ
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2275
mi
from 02139
Tucson, AZ
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2576
mi
from 02139
Fullerton, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2576
mi
from 02139
Fullerton, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2653
mi
from 02139
Santa Barbara, CA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2653
mi
from 02139
Santa Barbara, CA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1958
mi
from 02139
Grand Junction, CO
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1958
mi
from 02139
Grand Junction, CO
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from 02139
Cedar Rapids, IA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from 02139
Cedar Rapids, IA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
662
mi
from 02139
Ashland, KY
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
662
mi
from 02139
Ashland, KY
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 02139
Boston, MA
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1276
mi
from 02139
Omaha, NE
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1276
mi
from 02139
Omaha, NE
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
4763
mi
from 02139
Campinas,
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
4763
mi
from 02139
Campinas,
Click here to add this to my saved trials
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
609
mi
from 02139
Detroit, MI
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
609
mi
from 02139
Detroit, MI
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2
mi
from 02139
Boston, MA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Stanford University
2687
mi
from 02139
Palo Alto, CA
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Stanford University
2687
mi
from 02139
Palo Alto, CA
Click here to add this to my saved trials
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
268
mi
from 02139
Philadelphia, PA
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated:  12/31/1969
Royal Prince Alfred Hospital
10090
mi
from 02139
Camperdown,
Hemophilia B Gene Therapy With AAV8 Vector
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Status: Enrolling
Updated: 12/31/1969
Royal Prince Alfred Hospital
10090
mi
from 02139
Camperdown,
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Lafayette Family Cancer Center-EMMC
204
mi
from 02139
Brewer, ME
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Lafayette Family Cancer Center-EMMC
204
mi
from 02139
Brewer, ME
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
396
mi
from 02139
Buffalo, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
396
mi
from 02139
Buffalo, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
542
mi
from 02139
Cleveland, OH
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
542
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
640
mi
from 02139
Columbus, OH
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
640
mi
from 02139
Columbus, OH
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center-Weiler Hospital
175
mi
from 02139
Bronx, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center-Weiler Hospital
175
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
176
mi
from 02139
Bronx, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
180
mi
from 02139
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
180
mi
from 02139
New York, NY
Click here to add this to my saved trials
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
184
mi
from 02139
New York, NY
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
1605
mi
from 02139
Houston, TX
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1079
mi
from 02139
Rochester, MN
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1079
mi
from 02139
Rochester, MN
Click here to add this to my saved trials
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Royal Adelaide Hospital
10763
mi
from 02139
Adelaide,
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Royal Adelaide Hospital
10763
mi
from 02139
Adelaide,
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Providence St. Joseph Medical Center
2590
mi
from 02139
Burbank, CA
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Providence St. Joseph Medical Center
2590
mi
from 02139
Burbank, CA
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
1762
mi
from 02139
Denver, CO
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
1762
mi
from 02139
Denver, CO
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
MAB Oncology/Hematology
1121
mi
from 02139
Melbourne, FL
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
MAB Oncology/Hematology
1121
mi
from 02139
Melbourne, FL
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology of Indiana
801
mi
from 02139
Indianapolis, IN
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology of Indiana
801
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Center for Cancer & Blood Disorders
392
mi
from 02139
Bethesda, MD
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Center for Cancer & Blood Disorders
392
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Associates in Oncology and Hematology
389
mi
from 02139
Rockville, MD
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Associates in Oncology and Hematology
389
mi
from 02139
Rockville, MD
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Michigan
643
mi
from 02139
Ann Arbor, MI
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Michigan
643
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
University of Kansas
1248
mi
from 02139
Kansas City, MO
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
University of Kansas
1248
mi
from 02139
Kansas City, MO
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
183
mi
from 02139
Hackensack, NJ
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
183
mi
from 02139
Hackensack, NJ
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
176
mi
from 02139
Bronx, NY
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Alliance
184
mi
from 02139
New York, NY
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Alliance
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Gabrail Cancer Center
543
mi
from 02139
Canton, OH
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Gabrail Cancer Center
543
mi
from 02139
Canton, OH
Click here to add this to my saved trials
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Christ Hospital
735
mi
from 02139
Cincinnati, OH
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Christ Hospital
735
mi
from 02139
Cincinnati, OH
Click here to add this to my saved trials